| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Cancer Therapies | 23 |
$500 |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Amgen has a current Overall Rating of B (Positive). | 7 |
$25 |
| 25-Nov-2009 | New Constructs, LLC |
N/A
| AMGN: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 25-Nov-2009 | Pechala's Reports | Lubomir Pechala | AMGEN INC (AMGN=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 24-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (AMGN). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (AMGN). | 5 |
$18 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Nasdaq 100 Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 14 new Laggards. | 54 |
$40 |
| 23-Nov-2009 | Argus Research Corporation | David Coleman | Vickers Weekly Insider, 11/23/09 | 52 |
$50 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Nanotechnology & MEMS Industry Market Research and Competitive Analysis 2009 | 447 |
$299 |
0.16% Nasdaq 0.00%
Research Reports
